SHANGHAI, June 16 /PRNewswire-Asia/ -- Sundia MediTech Company, a Shanghai-based integrated pharmaceutical contract research company, announced today that its animal facility in Shanghai has passed the audit from a major European Pharmaceutical Company. The Sundia management and staff are praised for providing good facilities and programs for the care and use of laboratory animals.
The inspection and audit took place in May. The entire animal facility and life studies were inspected and audited. As stated in its official approval letter: "Our overall impression of Sundia is very positive. The personnel handling animals are well trained and engaged. All procedures are well described in SOPs, and the site is very well organized." As a result of an extensive on-site evaluation, the major European pharmaceutical company determined that Sundia MediTech animal facility is committed to the highest level of animal care and research practices.
Sundia has strong institutional commitment to the animal care and use program. The Institutional Animal Care and Use Committee (IACUC) is led by CEO, Dr. Xiaochuan Wang. The state-of-art animal facility was designed by SinoPharma Group Wuhan Institute. The operation of the animal facility has followed the extensive Standard Operating Procedures (SOP) and guidelines, and all records are well maintained. The animal facility was evaluated by Shanghai Animal Management Committee, and the Permit for Using Laboratory Animals was obtained in January this year.
"The success of passing the audit demonstrated our effort to provide
quality animal care for pharmaceutical research," said Dr. Jun Wang, Vice
President of Biology at Sundia MediTech. "We are very pleased to receive such
high praise from the leading major pharmaceutical company on the care and use
of laboratory animals. It demonstrates the quality of our laboratory testing
and the competence of our technic
|SOURCE Sundia Meditech Company, Ltd|
Copyright©2009 PR Newswire.
All rights reserved